Sionna Therapeutics, Inc. (NASDAQ:SION) Receives Average Rating of “Moderate Buy” from Brokerages

Sionna Therapeutics, Inc. (NASDAQ:SION) has received a consensus recommendation of “Moderate Buy” from the ten research firms that are currently covering the company, MarketBeat Ratings reports. Two analysts have rated the stock with a sell recommendation, six have given a buy recommendation and two have issued a strong buy recommendation on the company. The average 1 year price objective among brokers that have issued ratings on the stock in the last year is $50.5714.

A number of brokerages have recently issued reports on SION. Weiss Ratings restated a “sell (e+)” rating on shares of Sionna Therapeutics in a research note on Monday, December 29th. Citizens Jmp assumed coverage on shares of Sionna Therapeutics in a research note on Tuesday, February 24th. They issued a “market outperform” rating and a $63.00 target price on the stock. UBS Group reissued a “buy” rating on shares of Sionna Therapeutics in a research report on Monday, March 2nd. Lifesci Capital upgraded shares of Sionna Therapeutics to a “strong-buy” rating in a research note on Wednesday, February 25th. Finally, Guggenheim lifted their price objective on Sionna Therapeutics from $45.00 to $50.00 and gave the company a “buy” rating in a report on Monday, March 2nd.

Insider Buying and Selling

In other Sionna Therapeutics news, major shareholder Tpg Gp A, Llc sold 250,000 shares of the stock in a transaction on Thursday, January 22nd. The stock was sold at an average price of $40.00, for a total transaction of $10,000,000.00. Following the completion of the transaction, the insider directly owned 6,494,962 shares in the company, valued at $259,798,480. This represents a 3.71% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Peter A. Thompson sold 33,356 shares of the stock in a transaction on Wednesday, December 24th. The stock was sold at an average price of $44.55, for a total value of $1,486,009.80. Following the transaction, the director owned 3,561,655 shares of the company’s stock, valued at $158,671,730.25. This represents a 0.93% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 378,618 shares of company stock worth $15,731,751 in the last 90 days. 3.90% of the stock is owned by company insiders.

Institutional Investors Weigh In On Sionna Therapeutics

Large investors have recently made changes to their positions in the company. Russell Investments Group Ltd. acquired a new stake in shares of Sionna Therapeutics during the 3rd quarter worth about $30,000. BNP Paribas Financial Markets acquired a new position in Sionna Therapeutics in the second quarter valued at about $31,000. GF Fund Management CO. LTD. bought a new stake in Sionna Therapeutics during the fourth quarter worth about $36,000. Police & Firemen s Retirement System of New Jersey bought a new stake in Sionna Therapeutics during the second quarter worth about $45,000. Finally, Balyasny Asset Management L.P. acquired a new stake in shares of Sionna Therapeutics during the fourth quarter worth approximately $58,000.

Sionna Therapeutics Trading Up 2.5%

SION opened at $36.39 on Friday. The stock’s 50 day simple moving average is $38.18 and its 200-day simple moving average is $36.35. The stock has a market cap of $1.64 billion and a PE ratio of -18.66. Sionna Therapeutics has a 1 year low of $7.26 and a 1 year high of $45.00.

Sionna Therapeutics (NASDAQ:SION) last issued its earnings results on Monday, March 2nd. The company reported ($0.46) EPS for the quarter, topping the consensus estimate of ($0.61) by $0.15.

About Sionna Therapeutics

Sionna Therapeutics is a clinical-stage biotechnology company dedicated to developing next-generation RNA therapeutics for oncology and immunology indications. Leveraging proprietary lipid nanoparticle and coacervate delivery technologies, the company aims to overcome key challenges associated with stability, targeting and immune activation that have historically limited the clinical performance of mRNA-based medicines. Its strategic focus spans both solid tumors and hematological malignancies, as well as selected autoimmune disorders, reflecting a broad ambition to harness the power of messenger RNA in diverse therapeutic areas.

At the heart of Sionna’s approach is a platform that combines optimized ionizable lipids with bespoke surface chemistries to enhance payload delivery, intracellular release and endosomal escape.